[
    [
        {
            "time": "",
            "original_text": "“国产CT一哥”再冲IPO：净利近乎腰斩，能否成为下一个迈瑞？ 盈利能力下降",
            "features": {
                "keywords": [
                    "国产CT",
                    "IPO",
                    "净利腰斩",
                    "迈瑞",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗设备",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "\"国产CT一哥\"再冲IPO：净利近乎腰斩，能否成为下一个迈瑞？ 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]